Anadis clinical trial gets go-ahead
Wednesday, 03 September, 2008
The Israeli Ministry of Health has approved Anadis' (ASX:ANX) clinical protocol, clearing the way for trials of its mucositis treatment to begin within a month.
Mucostisis is a significant side effect of cancer therapy, experienced by between 20 and 100 per cent of patients, depending on the type of cancer and treatment.
Effects include painful mouth ulcerations and severe gastrointestinal symptoms.
The Anadis drug contains a unique formulation of Anadis' immune milk-derived anti LPS antibodies as well as other bioactives, and will be delivered using Anadis' oral delivery technology.
Anadis was recently awarded a grant from Vistech to help fund the drug development program.
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
